Brain stimulation reduces movement fluctuations
- Trial ID
- NCT01682668
- Official Title
- Role of the Subthalamic Nucleus in the Control of Movement: Physiopathology of Akinesia in Parkinson's Disease.
- Goal
- Brain stimulation reduces movement fluctuations
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Study Type
- INTERVENTIONAL
- Enrollment
- 180 participants
- Conditions
- Parkinson's Disease
- Interventions
- Bilateral subthalamic stimulation
Plain-Language Summary
Goal: Learn how the subthalamic nucleus drives akinesia and other movement problems in Parkinson's, and whether targeting it can reduce motor fluctuations, dyskinesias, and gait or balance issues. Approach: Bilateral deep brain stimulation of the subthalamic nucleus uses implanted electrodes to send continuous electrical pulses that normalize abnormal basal ganglia firing, improving movement and often allowing lower levodopa doses. Eligibility: Adults 18 to 70 with idiopathic Parkinson's are sought, including surgical candidates with motor complications and excellent levodopa responsiveness (greater than 50% improvement on testing), plus separate groups of non-operated and already-operated patients; people with dementia, unstable psychiatric illness, MRI contraindications, or other surgical risks are excluded.
Locations
- CIC-GHPS, Paris, France
- Groupe Hospitalier Pitie-Salpêtrière, Paris, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Bilateral subthalamic stimulation. Goal: Learn how the subthalamic nucleus drives akinesia and other movement problems in Parkinson's, and whether targeting it can reduce motor fluctuations, dyskinesias, and gait or balance issues. Approach: Bilateral deep brain stimulation of the subthalamic nucleus uses implanted electrodes to send continuous electrical pulses that normalize abnormal basal ganglia firing, improving movement and often allowing lower levodopa doses. Eligibility: Adults 18 to 70 with idiopathic Parkinson's are sought, including surgical candidates with motor complications and excellent levodopa responsiveness (greater than 50% improvement on testing), plus separate groups of non-operated and already-operated patients; people with dementia, unstable psychiatric illness, MRI contraindications, or other surgical risks are excluded.
- Who can participate?
- Participants must be between 18 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 12 years and 3 months.